2023 World Conference on Lung Cancer (Posters)-P2.09. Efficacy of Anlotinib in T790M-positive NSCLC Patients with Osimertinib Resistance: A Retrospective and Exploratory Study

P2.09. Efficacy of Anlotinib in T790M-positive NSCLC Patients with Osimertinib Resistance: A Retrospective and Exploratory Study - PDF(Slides)

Back to course

Pdf Summary

A retrospective and exploratory study was conducted to investigate the efficacy of Anlotinib in T790M-positive non-small cell lung cancer (NSCLC) patients who had acquired resistance to Osimertinib. The study aimed to compare the effectiveness of antiangiogenic-based therapy (Anlotinib or Bevacizumab), immunotherapy, and chemotherapy in these patients.<br /><br />The study collected data from 268 patients with secondary EGFR-T790M mutation who were resistant to Osimertinib. The therapeutic efficacy of antiangiogenic-based therapy, immunotherapy, and chemotherapy was compared. The results showed that progression-free survival (PFS) was significantly longer in the antiangiogenic-based therapy group compared to the immunotherapy and chemotherapy groups. The overall response rate (ORR) and disease control rate (DCR) were also higher in the antiangiogenic-based therapy group. Subgroup analysis suggested that Anlotinib-based therapy may provide more benefits than Bevacizumab-based therapy in terms of both PFS and overall survival (OS). <br /><br />In vitro assays were conducted to verify the therapeutic effects of Anlotinib alone or in combination with Osimertinib in T790M-mutant H1975 cell line with acquired Osimertinib resistance. The results demonstrated that Anlotinib exerted potent cytotoxicity to the cell line. Combined with Osimertinib, it showed even stronger cytotoxic effects.<br /><br />Overall, the study suggests that antiangiogenic-based therapy, specifically Anlotinib, may improve PFS and OS in NSCLC patients with acquired resistance to Osimertinib. These findings support the notion that Anlotinib-based therapy could be a promising treatment option for this group of patients. Further research and clinical trials are warranted to validate and expand on these results.

Asset Subtitle

Ya Chen

Meta Tag

Speaker Ya Chen

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective study

efficacy

Anlotinib

T790M-positive

NSCLC

acquired resistance

antiangiogenic therapy

chemotherapy

progression-free survival

cytotoxicity